CA-CEPTON-TECHNOLOGIES
11.10.2021 15:02:06 CEST | Business Wire | Press release
Cepton Technologies, Inc., an innovative provider of smart lidar solutions , announced today its membership in the Qualcomm® Smart Cities Accelerator Program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005191/en/
The Qualcomm Smart Cities Accelerator Program brings technologies and companies together to collaborate, innovate, and accelerate the rollout of smart cities and smart connected spaces globally. Cepton believes its presence in this ecosystem aligns with Qualcomm Technologies, Inc.’s vision of bringing efficient, safe, and advanced technology to fast-growing urban environments. With its membership, Cepton aims to advance the use of lidar-based solutions with ecosystem members of the Qualcomm Smart Cities Accelerator Program across smart cities and smart connected spaces.
Through the Qualcomm® IoT Services Suite, Cepton and one of its key partners in smart spaces, The Indoor Lab, plan to collaborate with Qualcomm Technologies in offering Smart Venues as a Service , utilizing a lidar-based crowd analytics system which adheres to the privacy concerns and optimizes the utilization of spaces.
With its high-accuracy, 3D perception capabilities and 24/7 availability , lidar can enable a wide range of applications to help build safer, smarter, and better-connected environments. Thanks to their anonymized data, lidars maximize protection of people’s privacy as they collect useful information to help drive intelligent decisions in smart cities and smart spaces. Cepton has been working with global partners to enable the transformation of transportation infrastructure, public venues and large commercial facilities using smart lidar solutions. For example, Cepton’s partnership with The Indoor Lab deployed a lidar-based crowd analytics solution as a pilot project at an Orlando International Airport terminal in 2020 to offer anonymous foot fall tracking, helping maintenance crews in targeted cleaning and travelers in avoiding crowded areas.
“We are proud to join Qualcomm Technologies’ network of technology innovators through the Qualcomm Smart Cities Accelerator Program as we work to help advance the future of smart infrastructure with our lidar technologies,” said Dr. Jun Pei, CEO of Cepton. “To date, our technology has been successfully used to enable real-time traffic and pedestrian monitoring at road and rail intersections , free-flow electronic tolling systems , critical infrastructure security , and crowd analytics . By joining the Qualcomm Smart Cities Accelerator Program ecosystem, we look forward to making our technologies more accessible on a global scale.”
“Our partnership with Cepton has been invaluable to establish The Indoor Lab as a market leader for lidar-based analytics,” said Patrick Blattner, Co-Founder and Chief Product Officer of The Indoor Lab . “Last week at the 3rd Annual Qualcomm Smart Cities Accelerate Event, we were proud to showcase our solution and its wide variety of applications to the global Qualcomm Smart Cities Accelerator Program ecosystem.”
"We are pleased to welcome Cepton as a member of our cutting-edge Qualcomm Smart Cities Accelerator Program. We look forward to working together to bring cutting-edge smart lidar solutions and applications to a variety of urban environments and collaborating to offer Smart Venues as a Service through the Qualcomm® IoT Services Suite," said Sanjeet Pandit, Senior Director, Business Development, and Global Head of Smart Cities, Qualcomm Technologies, Inc.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Smart Cities Accelerator Program is a program of Qualcomm Technologies, Inc. and/or its subsidiaries.
Qualcomm IoT Services Suite is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005191/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom